|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,641.20 INR | +3.57% |
|
+6.26% | +6.89% |
| Market Cap | 45TCr 466.85Cr 409.9Cr 382.33Cr 351.37Cr 658.71Cr 669.45Cr 4.52TCr 1.77TCr 22TCr 1.75TCr 1.71TCr 77TCr | P/E 2027 * |
38.9x | P/E 2028 * | 34.5x |
|---|---|---|---|---|---|
| Enterprise Value | 45TCr 466.85Cr 409.9Cr 382.33Cr 351.37Cr 658.71Cr 669.45Cr 4.52TCr 1.77TCr 22TCr 1.75TCr 1.71TCr 77TCr | EV / Sales 2027 * |
10.7x | EV / Sales 2028 * | 9.62x |
| Free-Float |
24.37% | Yield 2027 * |
1.12% | Yield 2028 * | 1.12% |
Last Transcript: GlaxoSmithKline Pharmaceuticals Limited
| 1 day | +3.57% | ||
| 1 week | +6.26% | ||
| Current month | +7.76% | ||
| 1 month | +11.97% | ||
| 3 months | +8.02% | ||
| 6 months | +12.92% | ||
| Current year | +6.89% |
| 1 week | 2,455 |  | 2,675.1 |
| 1 month | 2,336.1 | | 2,675.1 |
| Current year | 2,088 | | 2,715.15 |
| 1 year | 2,088 | | 3,202.8 |
| 3 years | 1,387.9 | | 3,515.95 |
| 5 years | 1,228 | | 3,515.95 |
| 10 years | 1,020 | | 3,515.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 56 | 01/12/2022 |
Ronojit Biswas
DFI | Director of Finance/CFO | - | 01/04/2026 |
Shalini Menon
CTO | Chief Tech/Sci/R&D Officer | - | 08/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Subesh Williams
BRD | Director/Board Member | 64 | 07/04/2017 |
Renu Sud Karnad
CHM | Chairman | 73 | 01/04/2019 |
| Director/Board Member | 59 | 18/05/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.57% | +6.26% | -16.28% | +88.72% | 450.49Cr | |
| +1.93% | +6.43% | +50.20% | +168.28% | 1,06800Cr | |
| +0.29% | +7.20% | +58.48% | +53.57% | 64TCr | |
| +2.45% | +3.88% | +38.32% | +76.82% | 45TCr | |
| +2.17% | +10.91% | +41.94% | +35.03% | 35TCr | |
| +1.46% | +5.93% | +40.44% | +43.69% | 30TCr | |
| +0.40% | +4.52% | +19.79% | +20.93% | 27TCr | |
| +2.73% | +2.26% | -25.81% | -36.98% | 22TCr | |
| +4.48% | +7.94% | +28.22% | +66.53% | 20TCr | |
| +2.91% | +0.83% | +15.59% | +75.56% | 16TCr | |
| Average | +1.85% | +2.74% | +25.09% | +59.22% | 36.68TCr | |
| Weighted average by Cap. | +1.01% | +2.85% | +39.01% | +81.21% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4.2TCr 44Cr 38Cr 36Cr 33Cr 62Cr 63Cr 424.34Cr 166.21Cr 2.08TCr 164.46Cr 160.91Cr 7.18TCr | 4.65TCr 49Cr 43Cr 40Cr 37Cr 68Cr 70Cr 469.81Cr 184.02Cr 2.3TCr 182.09Cr 178.16Cr 7.95TCr |
| Net income | 1.14TCr 12Cr 10Cr 9.76Cr 8.97Cr 17Cr 17Cr 115.38Cr 45Cr 564.26Cr 45Cr 44Cr 1.95TCr | 1.25TCr 13Cr 11Cr 11Cr 9.85Cr 18Cr 19Cr 126.76Cr 50Cr 619.89Cr 49Cr 48Cr 2.14TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/26/28 | ₹2,641.20 | +3.57% | 4,963 |
| 27/26/27 | ₹2,550.20 | +1.47% | 2,697 |
| 24/26/24 | ₹2,513.25 | +0.76% | 3,064 |
| 23/26/23 | ₹2,494.20 | -2.23% | 3,198 |
| 22/26/22 | ₹2,551.10 | +1.83% | 4,731 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLAXO Stock
Select your edition
All financial news and data tailored to specific country editions
